Late-night SpaceX rocket launch in Florida: When to see liftoff from Sebastian, Vero Beach
A SpaceX Falcon 9 rocket will potentially carry Starlink internet-beaming satellites into low-Earth orbit, a Federal Aviation Administration operations plan advisory shows.
Rockets here launch from NASA's Kennedy Space Center or nearby Cape Canaveral Space Force Station.
Weather permitting and depending on cloud cover, a rocket launch from Florida's Space Coast could be visible as far north as Jacksonville Beach and Daytona Beach to as far south as Vero Beach and West Palm Beach.
When there's a launch window in the middle of the night or very early morning, there's an opportunity for unique photos — the rocket lights up the dark sky and the contrail after makes for a great photo.
Below is more information about the SpaceX rocket launch in Florida and suggestions on where to watch them from here.
Is there a launch today? Is there a launch today? Upcoming SpaceX, NASA, ULA rocket launch schedule at Cape Canaveral
For questions or comments, email FLORIDA TODAY Space Reporter Rick Neale at rneale@floridatoday.com or Space Reporter Brooke Edwards at bedwards@floridatoday.com. For more space news from the USA TODAY Network, visit floridatoday.com/space.
Mission: A SpaceX Falcon 9 rocket will launch the next batch of Starlink internet satellites into low-Earth orbit, a Federal Aviation Administration operations plan advisory indicates.
Launch window: 1:48 a.m. to 6:18 a.m. ET Tuesday, July 8, 2025
Launch location: Launch Complex 40 at Cape Canaveral Space Force Station in Cape Canaveral, Florida
Sonic booms for Space Coast of Florida (Merritt Island, Melbourne area): No
Trajectory: Northeast
Live coverage starts 90 minutes before liftoff at : You can watch live rocket launch coverage from USA TODAY Network's Space Team, which consists of FLORIDA TODAY space reporters Rick Neale and Brooke Edwards and visuals journalists Craig Bailey, Malcolm Denemark and Tim Shortt. Our Space Team will provide up-to-the-minute updates in a mobile-friendly live blog, complete with a countdown clock, at floridatoday.com/space, starting 90 minutes before liftoff. You can download the free FLORIDA TODAY app, which is available in the App Store or Google Play, or type into your browser.
Shown is the National Weather Service-Melbourne radar, which shows conditions in real-time for the Space Coast, Brevard County, Orlando and other parts of Florida. The current date and time show up on the bottom right of this radar embed; otherwise, you may need to clear your cache.
Sebastian Inlet State Park, 9700 S. State Road A1A, Melbourne Beach, Florida (cost to enter)
Wabasso Beach Park, 1808 Wabasso Beach Road, Wabasso, Florida
Ambersands Beach Park, 12566 N. SR A1A, Vero Beach, Florida (free parking)
South Beach Park, 1700 Ocean Drive, Vero Beach, Florida (free parking)
Merrill Barber Bridge in Vero Beach, Florida
Alma Lee Loy Bridge in Vero Beach, Florida
Fort Pierce Inlet State Park, 905 Shorewinds Drive, Fort Pierce, Florida
Blind Creek Beachside North and South, 5460 S. Ocean Drive, Fort Pierce, Florida
Blue Heron Beach, 2101 Blue Heron Blvd., Fort Pierce, Florida
Frederick Douglass Memorial Park, 3600 S. Ocean Drive, Fort Pierce, Florida
Dollman Park Beachside, 9200 S. Ocean Drive, Jensen Beach, Florida
Herman's Bay Beach, 7880 S. Ocean Drive, Jensen Beach, Florida
John Brooks Park Beachside, 3300 S. Ocean Drive, Fort Pierce, Florida
Middle Cove Beach, 4600 S. Ocean Drive, Fort Pierce, Florida
Normandy Beach in Jensen Beach, Florida
Pepper Park Beachside, 3302 N. SR A1A, Fort Pierce, Florida
Walton Rocks Beach, 6700 S. Ocean Drive, Jensen Beach, Florida (dog park)
Waveland Beach, 10350 S. Ocean Drive, Jensen Beach, Florida
State Road A1A causeway in Stuart, Florida
House of Refuge and beach, 301 S.E. MacArthur Blvd., Stuart, Florida
This article originally appeared on Treasure Coast Newspapers: SpaceX rocket launch in Florida: What time does Falcon 9 lift off?
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
First Lung Organoid with Organ-Specific Blood Vessels
Advanced lab-grown tissues help show how special lung cells develop, shedding light on rare ACDMPV disease and suggesting potential ways to repair damage from viral infections such as COVID-19 CINCINNATI, June 30, 2025 /PRNewswire/ -- A team of experts at Cincinnati Children's reports another powerful step forward in organoid medicine: success at making human lung tissue that can produce its own blood vessels. Their findings, published in the same month as a similar success involving liver organoids, reflect a new wave of advanced lab-grown tissues that can be used immediately in many research applications while moving ever closer to serving as living tissues that can directly repair damaged organs. Details were posted online June 30, 2025, in the journal Cell. "Prior to our study, the development of lung organoids with organotypic vasculature had not been achieved," says co-corresponding author Mingxia Gu, MD, PhD. "Notably, this method also could be applied to other organ systems such as intestine and colon." Gu, now at UCLA, was a member of the Center for Stem Cell and Organoid Medicine (CuSTOM) and Division of Pulmonary Biology at Cincinnati Children's while this research was conducted. Co-first and co-corresponding author Yifei Miao, PhD, (now at the Chinese Academy of Sciences, Beijing) also was with Cincinnati Children's for this work. Co-corresponding author Minzhe Guo, PhD, remains with Cincinnati Children's along with several co-authors involved in this study. Overcoming a major challenge Researchers have been working for years to grow organoids -- sometimes called "organs in a dish." Creating organoids involves converting mature human cells (such as blood or tissue cells) back into fetal-like stem cells that can be coaxed into growing a wide range of other tissue types. Unlike disconnected human cells kept alive in a dish, these are growing, developing mini-organs that form into seed-sized spheres that mimic the unique functions of full-sized organs. Intestines that absorb and secrete. Stomachs that produce digestive acids. Hearts that pulse. Brain tissues with firing nerve cells and so on. Cincinnati Children's has been a leader in organoid development since 2010 when experts here produced the world's first functional intestinal organoid grown from induced pluripotent stem cells (iPSCs). More recently, the challenge has been learning how to grow organoid tissues that can connect with the rest of the body to integrate nerve connections, blood vessels, bile ducts, immune systems and more. During pregnancy, these differing tissue types naturally find each other as the fetus matures and becomes more complex. Organoid developers seek to re-produce these steps in the laboratory, which eventually may allow people to receive custom-grown tissues that could patch damage or boost disrupted functions. Simpler forms of organoids have already begun transforming medical research, allowing many scientists to use living human tissue models to study disease while reducing current reliance on animal models to develop new medicines. But without the ability to make internal blood vessels, the tiny seeds lack the ability to grow into larger, more useful tissues. How the team solved the vascular riddle The new study thoroughly recounts the results of many experiments the team conducted to demonstrate success at inducing blood vessel formation. The work spanned four years and involved more than 20 people at Cincinnati Children's plus collaborations with experts at several other organizations. "The challenge in vascularizing endodermal organs, particularly the lung, stems from different signaling requirements for lung epithelial versus vascular differentiation," says Miao. "Our success in this endeavor is attributable to our unique differentiation method." In essence, the team grew iPSCs from multiple cell types then found the right moment to introduce them to each other. The resulting cell signals helped flip a developmental switch so that progenitor cells that could have become either blood vessels or the outer walls of the lung wound up becoming blood vessels. In achieving this vital step, the team: Produced lung organoids that include respiratory bronchial epithelial cells (RAS cells), a human cell type not previously reported in conventional lung organoid models. Pinned down the developmental moments when a rudimentary gut tube begins to send some cells to form the lungs while sending other cells to form the stomach and intestine. While the basic steps of this transformation have been studied in animals, it had not been possible to study this stage of development in humans without killing fetuses. Demonstrated that the rare disease ACDMPV occurs when cell signaling "crosstalk" gets disrupted during this early blood vessel formation stage. Within days of birth, infants born with Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV) struggle to breathe because their lungs' air sacs (alveoli) and blood vessels are malformed. Nearly all infants with this condition die within the first month of life, according to the National Organization for Rare Disorders. Revealed key functional information about the cells involved in gas exchange inside the human lung. Their learnings help explain the damage within tiny blood capillaries that occurs in the lungs in response to injuries. These new clues offer fresh ideas for developing ways to protect and potentially restore affected lung tissues. What's Next? Cincinnati Children's has filed patent applications related to the methods developed here to produce organoids with blood vessel formation capabilities and the CuSTOM team is moving to further develop this technology. "We look forward to continuing to learn more about the fundamental biology involved in organ formation and applying those discoveries to improving outcomes across a wide range of difficult human diseases and conditions," says Aaron Zorn, PhD, co-director of CuSTOM and director of the Division of Developmental Biology. In addition to publishing these findings in Cell, co-authors plan to present their work at the Keystone conference in Kyoto, Japan (iPSCs: Progress, Opportunities, and Challenges) in January 2026. About the study Cincinnati Children's co-equal first authors were Miao, Nicole Pek, BS, and Cheng Tan, MD. Contributing co-authors from Cincinnati Children's were Cheng Jiang, MS, Zhiyun Yu, PhD, Kentaro Iwasawa, MD, PhD, Min Shi, MD, PhD, Daniel Kechele, PhD, Nambirajan Sundaram, PhD, Victor Pastrana-Gomez, MSTP student, Debora Sinner, PhD, Cheng-Lun Na, PhD, Keishi Kishimoto, PhD, Jason Tchieu, PhD, Jeffrey Whitsett, MD, Kyle McCracken, MD, PhD, Michael Helmrath, MD, James Wells, PhD, Takanori Takebe, MD, PhD, and Aaron Zorn, PhD. Contributing co-authors included experts from Harvard Medical School, Icahn School of Medicine at Mount Sinai, Sophia Children's Hospital (The Netherlands), Boston University This research also was supported by the Discover Together Biobank, the Bio-Imaging and Analysis Facility, and the Integrated Pathology Research Core at Cincinnati Children's and the University of Cincinnati Proteomics Laboratory. Funding sources for this work included: the National Institutes of Health (R01HL166283, DK128799-01, N01-75N92020C00005 and R01HL095993); an Endowed Scholar Award from the Cincinnati Children's Research Foundation; the American Heart Association (1013861 and 906513); the Falk Transformational Awards Program; and the Brigham Research Institute. Learn more about working with CuSTOM Learn how donors can support ongoing organoid research at Cincinnati Children's View original content to download multimedia: SOURCE Cincinnati Children's Hospital Medical Center Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
NASA to Provide Coverage of Progress 92 Launch, Space Station Docking
WASHINGTON, June 30, 2025 /PRNewswire/ -- NASA will provide live coverage of the launch and docking of a Roscosmos cargo spacecraft delivering approximately three tons of food, fuel, and supplies to the Expedition 73 crew aboard the International Space Station. The unpiloted Roscosmos Progress 92 spacecraft is scheduled to launch at 3:32 p.m. EDT, Thursday, July 3 (12:32 a.m. Baikonur time, Friday, July 4), on a Soyuz rocket from the Baikonur Cosmodrome in Kazakhstan. Live launch coverage will begin at 3:10 p.m. on NASA+. Learn how to watch NASA content through a variety of platforms, including social media. After a two-day, in-orbit journey to the station, the spacecraft will dock autonomously to the space-facing port of the orbiting laboratory's Poisk module at 5:27 p.m. on Saturday, July 5. NASA's rendezvous and docking coverage will begin at 4:45 p.m. on NASA+. The Progress 92 spacecraft will remain docked to the space station for approximately six months before departing for re-entry into Earth's atmosphere to dispose of trash loaded by the crew. Ahead of the spacecraft's arrival, the Progress 90 spacecraft will undock from the Poisk module on Tuesday, July 1. NASA will not stream undocking. The International Space Station is a convergence of science, technology, and human innovation that enables research not possible on Earth. For nearly 25 years, NASA has supported a continuous U.S. human presence aboard the orbiting laboratory, through which astronauts have learned to live and work in space for extended periods of time. The space station is a springboard for developing a low Earth economy and NASA's next great leaps in exploration, including missions to the Moon under Artemis and, ultimately, human exploration of Mars. Learn more about the International Space Station, its research, and crew, at: View original content to download multimedia: SOURCE NASA Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
SciBase: A new important customer in the US, Palm Beach Dermatology Group, has placed an initial order for 6 Nevisense.
STOCKHOLM, July 7, 2025 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of augmented intelligence-based solutions for skin disorders, is pleased to announce that Palm Beach Dermatology Group has purchased Nevisense, diagnostic platform, to enhance early detection of melanoma. The initial order, which has been delivered, consists of 6 Nevisense and electrodes to an approximative total order value of KUSD 50 and will generate recurring electrodes sales. For more than 30 years, Palm Beach Dermatology Group has been a leader in skin care. They focus on advanced treatments, putting patients first, and clinical research. By adding Nevisense, they now offer a non-invasive, AI-based diagnostic tool at point of care. Melanoma, the deadliest form of skin cancer, remains a serious and growing public health concern in the United States. According to the American Cancer Society, an estimated 190,000 new cases of melanoma will be diagnosed in the U.S. in 2025. Tragically, approximately 8,290 people are expected to die from melanoma this year. However, early detection is key - when found at an early stage, melanoma has an almost 100% cure rate. "At Palm Beach Dermatology Group, we are always looking to integrate the most innovative and evidence-based technologies into our practice," said Dr. Adam Plotkin, dermatologist and CEO of Palm Beach Dermatology Group. "Nevisense offers a layer of key diagnostic data that will help us detect melanoma at earlier stages, which can make a life-saving difference." We're excited to have Palm Beach Dermatology Group join our growing network of clinical partners. Known for their excellent patient care and strong research program, it makes them an ideal champion for Nevisense in Florida. Together, we're setting a new standard for melanoma detection," said Pia Renaudin, CEO of SciBase. For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@ About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: Palm Beach final - eng View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
